← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

AMRN logoAmarin Corporation plc(AMRN)Earnings, Financials & Key Ratios

AMRN•NASDAQ
$14.90
$310M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCommercial Specialty Pharma
AboutAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Show more
  • Revenue$214M-6.5%
  • EBITDA-$11M+87.7%
  • Net Income-$39M+52.8%
  • EPS (Diluted)-1.80+55.0%
  • Gross Margin56.57%+58.9%
  • EBITDA Margin-5.11%+86.8%
  • Operating Margin-6.53%+83.7%
  • Net Margin-18.16%+49.5%
  • ROE-8.21%+48.2%
  • ROIC-2.95%+84.3%
  • Debt/Equity0.03+66.7%
  • Interest Coverage-5148.71+53.3%
Technical→

AMRN Key Insights

Amarin Corporation plc (AMRN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Trading at only 0.7x book value

✗Weaknesses

  • ✗Profits declining 16.6% over 5 years
  • ✗Sales declining 19.0% over 5 years

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

AMRN Price & Volume

Amarin Corporation plc (AMRN) stock price & volume — 10-year historical chart

Loading chart...

AMRN Growth Metrics

Amarin Corporation plc (AMRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years10.08%
5 Years-19.04%
3 Years-16.67%
TTM0.33%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM61.77%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM62.14%

Return on Capital

10 Years-25.59%
5 Years-9.12%
3 Years-10.38%
Last Year-2.84%

AMRN Recent Earnings

Amarin Corporation plc (AMRN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 29, 2026
EPS
$0.03
Est $0.01
-400.0%
Revenue
$45M
Est $44M
+3.1%
Q1 2026
Feb 25, 2026
EPS
$0.01
Est $0.07
-85.7%
Revenue
$49M
Est $51M
-2.8%
Q4 2025
Oct 29, 2025
EPS
$0.01
Est $0.08
-87.5%
Revenue
$49M
Est $51M
-4.1%
Q3 2025
Jul 30, 2025
EPS
$0.03
Est $0.66
+95.5%
Revenue
$47M
Est $42M
+10.9%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 29, 2026
$0.03vs $0.01-400.0%
$45Mvs $44M+3.1%
Q1 2026Feb 25, 2026
$0.01vs $0.07-85.7%
$49Mvs $51M-2.8%
Q4 2025Oct 29, 2025
$0.01vs $0.08-87.5%
$49Mvs $51M-4.1%
Q3 2025Jul 30, 2025
$0.03vs $0.66+95.5%
$47Mvs $42M+10.9%
Based on last 12 quarters of dataView full earnings history →

AMRN Peer Comparison

Amarin Corporation plc (AMRN) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
ELAN logoELANElanco Animal Health IncorporatedDirect Competitor13.06B26.16-55.666.22%-4.95%-3.64%0.61
ACAD logoACADACADIA Pharmaceuticals Inc.Direct Competitor3.68B21.489.3811.87%36.49%41.9%0.04
SUPN logoSUPNSupernus Pharmaceuticals, Inc.Direct Competitor2.96B51.45-75.668.63%-3.74%-2.73%0.04
HRMY logoHRMYHarmony Biosciences Holdings, Inc.Direct Competitor1.89B32.7812.1021.51%18.27%18.24%0.02
PRGO logoPRGOPerrigo Company plcDirect Competitor1.69B12.26-1.19-2.75%-43.5%-50.65%1.35
PAHC logoPAHCPhibro Animal Health CorporationDirect Competitor2.38B58.6449.2827.37%6.29%30.81%2.67
ABBV logoABBVAbbVie Inc.Product Competitor362.56B204.9886.498.57%6.91%62.15%
PFE logoPFEPfizer Inc.Product Competitor150.77B26.5119.49-1.65%11.83%8.34%0.78

Compare AMRN vs Peers

Amarin Corporation plc (AMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ELAN

Most directly comparable listed peer for AMRN.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare AMRN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ELAN, ACAD, SUPN, HRMY

AMRN Income Statement

Amarin Corporation plc (AMRN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue181.1M229.21M429.75M614.06M583.19M369.19M306.91M228.61M213.65M214.88M
Revenue Growth %39.22%26.56%87.49%42.89%-5.03%-36.69%-16.87%-25.51%-6.55%0.33%
Cost of Goods Sold44.95M54.54M96.02M131.44M121.33M126.71M141.37M147.23M92.78M102.11M
COGS % of Revenue24.82%23.8%22.34%21.41%20.8%34.32%46.06%64.4%43.43%-
Gross Profit
136.15M▲ 0%
174.67M▲ 28.3%
333.74M▲ 91.1%
482.62M▲ 44.6%
461.86M▼ 4.3%
242.48M▼ 47.5%
165.54M▼ 31.7%
81.38M▼ 50.8%
120.87M▲ 48.5%
112.77M▲ 0%
Gross Margin %75.18%76.2%77.66%78.59%79.2%65.68%53.94%35.6%56.57%52.48%
Gross Profit Growth %42.24%28.29%91.07%44.61%-4.3%-47.5%-31.73%-50.84%48.52%-
Operating Expenses181.71M282.9M358.01M502.27M451.36M348.35M233.13M173.18M134.81M150.13M
OpEx % of Revenue100.33%123.42%83.31%81.8%77.4%94.36%75.96%75.75%63.1%-
Selling, General & Admin134.55M227M323.62M463.31M408.33M304.42M199.94M152.31M115M99.52M
SG&A % of Revenue74.29%99.03%75.3%75.45%70.02%82.45%65.15%66.62%53.83%-
Research & Development47.16M55.9M34.39M38.96M29.31M30.41M22.22M20.87M19.81M18.45M
R&D % of Revenue26.04%24.39%8%6.34%5.03%8.24%7.24%9.13%9.27%-
Other Operating Expenses74K-326K0104K13.72M13.53M10.97M002M
Operating Income
-45.55M▲ 0%
-108.22M▼ 137.6%
-24.28M▲ 77.6%
-19.66M▲ 19.0%
10.5M▲ 153.4%
-105.87M▼ 1108.1%
-67.59M▲ 36.2%
-91.8M▼ 35.8%
-13.94M▲ 84.8%
-37.36M▲ 0%
Operating Margin %-25.15%-47.22%-5.65%-3.2%1.8%-28.68%-22.02%-40.15%-6.53%-17.38%
Operating Income Growth %30.58%-137.57%77.57%19.05%153.43%-1108.08%36.16%-35.82%84.81%-
EBITDA-44.84M-107.56M-23.42M-17.6M13.36M-102.77M-64.62M-88.78M-10.91M-34.42M
EBITDA Margin %-24.76%-46.92%-5.45%-2.87%2.29%-27.84%-21.06%-38.84%-5.11%-16.02%
EBITDA Growth %30.86%-139.87%78.23%24.85%175.9%-869.32%37.12%-37.39%87.71%62.58%
D&A (Non-Cash Add-back)715.59K667.87K859K2.05M2.86M3.1M2.96M3.01M3.03M2.93M
EBIT-45.05M-107.3M-15.86M-14.76M11.42M-103.79M-53.88M-77.19M-36.04M-5.19M
Net Interest Income-9.34M-7.8M1.87M2.3M1.09M2.8M11.86M13.4M10.85M10.41M
Interest Income429K1.07M8.5M4.9M1.22M2.82M11.86M13.4M10.85M10.41M
Interest Expense9.77M8.87M6.63M2.6M129K15K8K7K7K0
Other Income/Expense-9.26M-8.12M1.8M2.4M789K2.06M13.92M14.6M-22.11M2.64M
Pretax Income
-55.41M▲ 0%
-116.35M▼ 110.0%
-22.48M▲ 80.7%
-17.25M▲ 23.2%
11.29M▲ 165.4%
-103.81M▼ 1019.4%
-53.67M▲ 48.3%
-77.2M▼ 43.8%
-36.05M▲ 53.3%
-34.72M▲ 0%
Pretax Margin %-30.59%-50.76%-5.23%-2.81%1.94%-28.12%-17.49%-33.77%-16.87%-16.16%
Income Tax13.05M96K164K745K3.56M2M5.44M4.98M2.75M-1.11M
Effective Tax Rate %-23.55%-0.08%-0.73%-4.32%31.55%-1.92%-10.14%-6.45%-7.63%3.18%
Net Income
-67.86M▲ 0%
-116.44M▼ 71.6%
-22.64M▲ 80.6%
-18M▲ 20.5%
7.73M▲ 142.9%
-105.8M▼ 1468.9%
-59.11M▲ 44.1%
-82.18M▼ 39.0%
-38.8M▲ 52.8%
-33.61M▲ 0%
Net Margin %-37.47%-50.8%-5.27%-2.93%1.33%-28.66%-19.26%-35.95%-18.16%-15.64%
Net Income Growth %21.41%-71.58%80.55%20.51%142.94%-1468.91%44.13%-39.03%52.79%61.77%
Net Income (Continuing)-68.59M-116.44M-22.64M-18M7.73M-105.8M-59.11M-82.18M-38.8M-33.61M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)
-5.00▲ 0%
-7.80▼ 56.0%
-1.32▲ 83.1%
-1.00▲ 24.2%
0.38▲ 138.0%
-5.20▼ 1468.4%
-3.00▲ 42.3%
-4.00▼ 33.3%
-1.80▲ 55.0%
-1.62▲ 0%
EPS Growth %39.02%-56%83.08%24.24%138%-1468.42%42.31%-33.33%55%62.14%
EPS (Basic)-5.00-7.80-1.32-0.940.39-5.20-3.00-4.00-1.80-
Diluted Shares Outstanding13.53M14.86M17.13M19.09M20.12M20.06M20.38M20.55M20.75M20.8M
Basic Shares Outstanding13.53M14.86M17.13M18M19.8M20.06M19.7M20.55M20.75M20.8M
Dividend Payout Ratio----------

AMRN Balance Sheet

Amarin Corporation plc (AMRN) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets153.27M378M855M879.23M878.73M689.1M724.98M595.4M649.88M626.02M
Cash & Short-Term Investments73.64M249.23M644.59M500.93M454.13M309.36M320.66M294.22M302.79M307.82M
Cash Only73.64M249.23M644.59M186.96M219.45M217.67M199.25M121.04M134.86M131.06M
Short-Term Investments000313.97M234.67M91.69M121.41M173.18M167.93M176.76M
Accounts Receivable45.32M66.52M116.43M154.57M163.65M130.99M133.56M122.28M126.83M108.05M
Days Sales Outstanding91.33105.9398.8991.88102.43129.5158.84195.23216.68204.39
Inventory30.26M57.8M76.77M188.86M234.68M228.73M258.62M166.05M195.91M183.59M
Days Inventory Outstanding245.7386.81291.82524.45706658.89667.71411.65770.73657.21
Other Current Assets600K1.5M3.91M3.92M3.92M20.02M525K12.85M24.35M26.56M
Total Non-Current Assets8.33M7.72M27.2M86.79M189.34M197.08M106.7M89.95M20.89M19.75M
Property, Plant & Equipment28K63K10.87M10.07M9.09M9.95M8.42M7.61M6.47M6.01M
Fixed Asset Turnover6468.00x3638.32x39.53x60.98x64.19x37.11x36.43x30.05x33.01x31.44x
Goodwill0000000013.36M0
Intangible Assets8.13M7.48M15.26M13.82M23.55M21.78M19.3M16.39M012.73M
Long-Term Investments-1.74M0062.47M35M1.27M0000
Other Non-Current Assets174K174K1.07M432K121.71M164.08M78.97M65.95M1.05M53M
Total Assets
161.6M▲ 0%
385.71M▲ 138.7%
882.21M▲ 128.7%
966.02M▲ 9.5%
1.07B▲ 10.6%
886.18M▼ 17.0%
831.68M▼ 6.1%
685.35M▼ 17.6%
670.77M▼ 2.1%
645.76M▲ 0%
Asset Turnover1.12x0.59x0.49x0.64x0.55x0.42x0.37x0.33x0.32x0.32x
Asset Growth %-3.23%138.69%128.72%9.5%10.56%-17.03%-6.15%-17.59%-2.13%-31.95%
Total Current Liabilities108.53M157.26M242.25M307.44M370.68M259.48M259.28M179.95M194.46M179.64M
Accounts Payable25.16M37.63M49.95M105.88M114.92M64.6M52.76M40.37M45.35M48.15M
Days Payables Outstanding204.25251.83189.88294345.73186.09136.22100.07178.43156.32
Short-Term Debt22.83M34.24M50.13M0000000
Deferred Revenue (Current)1.64M1.22M2.34M2.93M2.65M2.2M2.34M000
Other Current Liabilities5.16M72M16.59M28.79M45.6M35.64M185.23M139.58M149.1M131.49M
Current Ratio1.41x2.40x3.53x2.86x2.37x2.66x2.80x3.31x3.34x3.34x
Quick Ratio1.13x2.04x3.21x2.25x1.74x1.77x1.80x2.39x2.33x2.33x
Cash Conversion Cycle132.79240.91200.83322.32462.69602.3690.33506.8808.99705.28
Total Non-Current Liabilities118.17M76.12M31.7M31.07M30.28M31.37M20.31M19.22M17.03M16.71M
Long-Term Debt99.83M46.11M0000006.08M5.58M
Capital Lease Obligations009.44M9.15M8.58M10.02M8.74M7.72M6.08M13.42M
Deferred Tax Liabilities1.74M000000000
Other Non-Current Liabilities1.15M10.52M3.75M6.21M7.65M8.21M9.06M11.5M4.87M39.87M
Total Liabilities226.7M233.38M273.95M338.52M400.97M290.85M279.59M199.17M211.49M196.35M
Total Debt122.66M80.35M59.57M9.15M8.58M10.02M8.74M7.72M12.16M5.58M
Net Debt49.02M-168.88M-585.01M-177.81M-210.88M-207.65M-190.51M-113.31M-122.7M-125.48M
Debt / Equity-0.53x0.10x0.01x0.01x0.02x0.02x0.02x0.03x0.03x
Debt / EBITDA----0.64x-----0.16x
Net Debt / EBITDA-----15.79x----3.65x
Interest Coverage-4.61x-12.09x-2.39x-5.67x88.52x-6919.33x-6734.75x-11027.57x-5148.71x-
Total Equity
-65.1M▲ 0%
152.33M▲ 334.0%
608.26M▲ 299.3%
627.5M▲ 3.2%
667.1M▲ 6.3%
595.33M▼ 10.8%
552.1M▼ 7.3%
486.18M▼ 11.9%
459.28M▼ 5.5%
449.41M▲ 0%
Equity Growth %-618.7%333.99%299.31%3.16%6.31%-10.76%-7.26%-11.94%-5.53%-40.05%
Book Value per Share-4.8110.2535.5232.8733.1529.6827.0923.6622.1321.61
Total Shareholders' Equity-65.1M152.33M608.26M627.5M667.1M595.33M552.1M486.18M459.28M449.41M
Common Stock208.77M246.66M269.17M290.12M294.03M299M302.76M305.3M310.18M314.06M
Retained Earnings-1.27B-1.39B-1.41B-1.43B-1.42B-1.53B-1.59B-1.67B-1.71B-1.72B
Treasury Stock-4.23M-10.41M-35.9M-51.08M-60.73M-61.77M-63.75M-65.33M-67.36M0
Accumulated OCI-816K000000000
Minority Interest0000000000

AMRN Cash Flow Statement

Amarin Corporation plc (AMRN) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations-32.84M-94.7M-9.37M-21.75M-66.53M-179.98M6.91M-31.02M6.74M6.74M
Operating CF Margin %-18.13%-41.32%-2.18%-3.54%-11.41%-48.75%2.25%-13.57%3.16%-
Operating CF Growth %54.28%-188.4%90.11%-132.18%-205.94%-170.53%103.84%-549.13%121.74%644.22%
Net Income-67.86M-116.44M-22.64M-18M7.73M-105.74M-59.34M-82.18M0-33.61M
Depreciation & Amortization708K669K859K2.04M2.86M3.09M2.98M3.01M0-97.21K
Stock-Based Compensation13.96M18.81M30.92M45.81M00017.7M0-3.95M
Deferred Taxes11.08M000000000
Other Non-Cash Items2.33M2.18M1.64M2.24M38.86M26.67M12M-5.73M-25.54M-22.77M
Working Capital Changes6.95M84K-20.14M-53.83M-115.98M-104.01M51.27M36.17M32.28M47.14M
Change in Receivables-25.33M-21.2M-49.91M-39.47M-8.34M32.98M-2.33M11.22M-3.83M-1.05M
Change in Inventory-9.75M-27.54M-18.97M-112.09M-167.05M-36.4M56.34M105.44M34.96M33.22M
Change in Payables40.27M37.6M65.91M114.74M51.51M-102.67M-164.63K-77.02M14.54M17.22M
Cash from Investing-12K-58K-2.48M-376.96M104.09M175.18M-25.62M-45.98M8.85M-11.72M
Capital Expenditures-12K-58K-2.48M-252K0-598.63K-535.07K000
CapEx % of Revenue0.01%0.03%0.58%0.04%0%0.16%0.17%---
Acquisitions00004K00000
Investments----------
Other Investing0-58K0000000-200.5M
Cash from Financing8.23M271.25M409.61M-58.91M-5.07M-378.77K230.89K-1.44M-2.04M-2.59M
Debt Issued (Net)11.57M-14.69M-31.65M-50.34M000000
Equity Issued (Net)-2.77M264.84M440.11M04.57M664.59K2.22M131.06K140.33K140.33K
Dividends Paid0000000000
Share Repurchases-2.77M000000000
Other Financing-569K21.1M1.16M-8.57M-9.64M-1.04M-1.99M-1.57M-2.18M-2.73M
Net Change in Cash
-24.61M▲ 0%
176.49M▲ 817.0%
397.77M▲ 125.4%
-457.62M▼ 215.0%
32.49M▲ 107.1%
-5.18M▼ 116.0%
-18.41M▼ 255.2%
-78.44M▼ 326.0%
13.52M▲ 117.2%
11.44M▲ 0%
Free Cash Flow
-32.85M▲ 0%
-94.76M▼ 188.5%
-11.84M▲ 87.5%
-22M▼ 85.7%
-66.53M▼ 202.4%
-179.98M▼ 170.5%
6.88M▲ 103.8%
-31.02M▼ 550.7%
6.74M▲ 121.7%
25.51M▲ 0%
FCF Margin %-18.14%-41.34%-2.76%-3.58%-11.41%-48.75%2.24%-13.57%3.16%11.87%
FCF Growth %54.27%-188.47%87.5%-85.73%-202.43%-170.53%103.82%-550.7%121.74%182.56%
FCF per Share-2.43-6.38-0.69-1.15-3.31-8.970.34-1.510.330.33
FCF Conversion (FCF/Net Income)0.48x0.81x0.41x1.21x-8.61x1.70x-0.12x0.38x-0.17x-0.76x
Interest Paid17.24M21.53M4.59M2.04M000000
Taxes Paid1.75M850K67K207K0003.98M03.31M

AMRN Key Ratios

Amarin Corporation plc (AMRN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)--266.98%-5.95%-2.91%1.19%-16.76%-10.3%-15.83%-8.21%-7.34%
Return on Invested Capital (ROIC)---543.64%-6.23%1.74%-18.82%-13.53%-18.75%-2.95%-2.95%
Gross Margin75.18%76.2%77.66%78.59%79.2%65.68%53.94%35.6%56.57%52.48%
Net Margin-37.47%-50.8%-5.27%-2.93%1.33%-28.66%-19.26%-35.95%-18.16%-15.64%
Debt / Equity-0.53x0.10x0.01x0.01x0.02x0.02x0.02x0.03x0.03x
Interest Coverage-4.61x-12.09x-2.39x-5.67x88.52x-6919.33x-6734.75x-11027.57x-5148.71x-
FCF Conversion0.48x0.81x0.41x1.21x-8.61x1.70x-0.12x0.38x-0.17x-0.76x
Revenue Growth39.22%26.56%87.49%42.89%-5.03%-36.69%-16.87%-25.51%-6.55%0.33%

AMRN SEC Filings & Documents

Amarin Corporation plc (AMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 29, 2026·SEC

Material company update

Mar 27, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 2, 2026·SEC

FY 2025

Mar 12, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 29, 2026·SEC

FY 2025

Oct 29, 2025·SEC

FY 2025

Jul 30, 2025·SEC

AMRN Frequently Asked Questions

Amarin Corporation plc (AMRN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Amarin Corporation plc (AMRN) reported $214.9M in revenue for fiscal year 2025. This represents a 899% increase from $21.5M in 1996.

Amarin Corporation plc (AMRN) saw revenue decline by 6.5% over the past year.

Amarin Corporation plc (AMRN) reported a net loss of $33.6M for fiscal year 2025.

Dividend & Returns

Amarin Corporation plc (AMRN) has a return on equity (ROE) of -8.2%. Negative ROE indicates the company is unprofitable.

Amarin Corporation plc (AMRN) generated $25.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More AMRN

Amarin Corporation plc (AMRN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.